US FDA GMP Inspection Programs

US FDA’s Quality Metrics Initiative and Inspection Planning

June 3, 2025 digi

US FDA’s Quality Metrics Initiative and Inspection Planning US FDA’s Quality Metrics Initiative: A Strategic Tool for Risk-Based Inspection Planning In a bid to enhance GMP compliance oversight and foster a culture of continuous improvement, the US Food and Drug Administration (FDA) launched the Quality Metrics Initiative. Designed as a voluntary program, this initiative encourages…

International GMP Inspection Standards and Harmonization, US FDA GMP Inspection Programs

FDA Drug Manufacturing Facility Classification Outcomes (NAI, VAI, OAI)

June 3, 2025 digi

FDA Drug Manufacturing Facility Classification Outcomes (NAI, VAI, OAI) Decoding FDA Facility Classification Outcomes: NAI, VAI, and OAI Explained When the US Food and Drug Administration (FDA) inspects a drug manufacturing facility, the outcome of the inspection is not just reflected in a Form 483 or the Establishment Inspection Report (EIR)—it is also summarized in…

International GMP Inspection Standards and Harmonization, US FDA GMP Inspection Programs

Understanding FDA’s NAI, VAI, OAI Ratings

June 4, 2025 digi

Understanding FDA’s NAI, VAI, OAI Ratings Understanding the Meaning and Impact of FDA’s NAI, VAI, and OAI Ratings After completing a GMP inspection, the US Food and Drug Administration (FDA) assigns a facility classification that reflects the severity of findings observed. These post-inspection ratings—No Action Indicated (NAI), Voluntary Action Indicated (VAI), and Official Action Indicated…

International GMP Inspection Standards and Harmonization, US FDA GMP Inspection Programs

FDA’s Remote Regulatory Assessment (RRA) Process

June 4, 2025 digi

FDA’s Remote Regulatory Assessment (RRA) Process Demystifying the FDA’s Remote Regulatory Assessment (RRA) Process The US Food and Drug Administration (FDA) introduced the Remote Regulatory Assessment (RRA) as an innovative alternative to traditional on-site inspections. This initiative, which gained prominence during the COVID-19 pandemic, allows the FDA to evaluate pharmaceutical manufacturing operations remotely. As part…

International GMP Inspection Standards and Harmonization, US FDA GMP Inspection Programs

US FDA’s Supply Chain Security Act and GMP Implications

June 4, 2025 digi

US FDA’s Supply Chain Security Act and GMP Implications GMP Implications of the US FDA’s Supply Chain Security Act (DSCSA) The Drug Supply Chain Security Act (DSCSA), enacted by the US FDA in 2013, has significantly transformed how pharmaceutical manufacturers handle traceability, product verification, and supply chain security. As the act moves towards full enforcement,…

International GMP Inspection Standards and Harmonization, US FDA GMP Inspection Programs

How to Request Inspection Records Through FOIA

June 4, 2025 digi

How to Request Inspection Records Through FOIA How to Request FDA Inspection Records Using FOIA: A GMP Compliance Tool Transparency is a cornerstone of US FDA regulatory practices, and one powerful mechanism that supports this transparency is the Freedom of Information Act (FOIA). For pharmaceutical professionals and GMP stakeholders, FOIA allows access to essential documents…

International GMP Inspection Standards and Harmonization, US FDA GMP Inspection Programs

Warning Letters vs. Import Alerts: What’s the Difference?

June 4, 2025 digi

Warning Letters vs. Import Alerts: What’s the Difference? Understanding the Difference Between FDA Warning Letters and Import Alerts When pharmaceutical manufacturers fall short of GMP expectations, the US Food and Drug Administration (FDA) may issue enforcement actions such as Warning Letters and Import Alerts. Although both are serious regulatory responses, they differ significantly in intent,…

International GMP Inspection Standards and Harmonization, US FDA GMP Inspection Programs

FDA Expectations for Analytical Method Validation

June 5, 2025 digi

FDA Expectations for Analytical Method Validation Meeting FDA Expectations for Analytical Method Validation in GMP Environments Analytical method validation is a foundational requirement in Good Manufacturing Practice (GMP) and a focal point during FDA inspections. It ensures the reliability, accuracy, and reproducibility of test methods used in pharmaceutical quality control. Whether validating a method for…

International GMP Inspection Standards and Harmonization, US FDA GMP Inspection Programs

US FDA Inspection Preparation Checklist

June 5, 2025 digi

US FDA Inspection Preparation Checklist Essential Checklist for Preparing Your Facility for a US FDA Inspection US FDA inspections are a pivotal part of regulatory oversight, determining a pharmaceutical facility’s compliance with Current Good Manufacturing Practices (cGMP) under 21 CFR Parts 210 and 211. Being prepared is not just about documentation—it’s about demonstrating control, traceability,…

International GMP Inspection Standards and Harmonization, US FDA GMP Inspection Programs

GMP Training Resources Provided by the FDA

June 5, 2025 digi

GMP Training Resources Provided by the FDA Leveraging FDA-Provided GMP Training Resources for Compliance Excellence Training is a foundational pillar of Good Manufacturing Practice (GMP) compliance. To ensure consistent application of quality systems, both new and experienced pharmaceutical professionals require structured, regulator-endorsed learning opportunities. The US Food and Drug Administration (FDA) offers a suite of…

International GMP Inspection Standards and Harmonization, US FDA GMP Inspection Programs